DYNAMICS OF CYTOKINE PROFILE IN PATIENTS WITH RHEUMATOID ARTHRITIS AS INFLUENCED BY INFLIXIMAB (REMIKEID) ADMINISTRATION

Abstract. Rheumatoid arthritis (RA) is a chronic autoimmune systemic disease with predominantly destructive lesions of peripheral joints, with prevalence of 0.6 to 1.6% in general population. An important pathogenetic role in this disease is now attributed to imbalance between pro- and antiinflammat...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	E. S. Zhugrova, V. I. Mazurov, A. M. Lila, K. A. Syssoev, S. V. Lapin, Areg A. Totolian
Formato:	article
Lenguaje:	RU
Publicado:	SPb RAACI 2014
Materias:	rheumatoid arthritis methotrexate tnfα cytokines infliximab das28 haq functional index Immunologic diseases. Allergy RC581-607
Acceso en línea:	https://doaj.org/article/21aea2d3e17f4045b69016b1763508be
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:21aea2d3e17f4045b69016b1763508be
record_format	dspace
spelling	oai:doaj.org-article:21aea2d3e17f4045b69016b1763508be2021-11-18T08:03:38ZDYNAMICS OF CYTOKINE PROFILE IN PATIENTS WITH RHEUMATOID ARTHRITIS AS INFLUENCED BY INFLIXIMAB (REMIKEID) ADMINISTRATION1563-06252313-741X10.15789/1563-0625-2008-2-3-251-260https://doaj.org/article/21aea2d3e17f4045b69016b1763508be2014-07-01T00:00:00Zhttps://www.mimmun.ru/mimmun/article/view/167https://doaj.org/toc/1563-0625https://doaj.org/toc/2313-741XAbstract. Rheumatoid arthritis (RA) is a chronic autoimmune systemic disease with predominantly destructive lesions of peripheral joints, with prevalence of 0.6 to 1.6% in general population. An important pathogenetic role in this disease is now attributed to imbalance between pro- and antiinflammatory cytokines. Clinical introduction of biological preparations, such as Infliximab (monoclonal antibodies to TNFα) within last years have changed therapeutic approach to treatment of rheumatic diseases. The aim of our research was to evaluate dynamics of pro- and antiinflammatory cytokine profile in the patients with rheumatoid arthritis (RА) during combined therapy with Infliximab and Methotrexate (MT). The study included 30 patients (27 females, 3 males, mean age of 52.5±2.0 years) who received combined therapy with МТ and Infliximab (Inx). Inx was initially injected at a single dose of 3 mg/kg intravenously, followed by administration 2 and 6 weeks later, and then repeated every 8 weeks. Regular examination of the patients included clinical and laboratory studies (ESR, levels of IL-6, IL-8, TNFα, IL-4, IL-10, GSM-CSF, IFNγ). Levels of antibodies against Infliximab in the groups of RА patients were determined before treatment and 22 weeks later. Efficiency of the therapy was estimated according to DAS28 3V Index and to HAQ Questionnaire.Upon decreased activity of disease, as assessed by DAS28, and improvement of HAQ parameters, a marked decrease in proinflammatory cytokine levels (IL-6, IL-8, TNFα) was detected, that confirming a pathogenetic significance of cytokine in RА patients. In patients with marked clinical effect (group I), an initially normal contents of TNFα was found in blood serum, and this group showed better response to Infliximab therapy, than groups II and III (resp., moderate and absent response) with initially high contents of TNFα and other cytokines, that was proven by correlations with ACR criteria and HAQ functional index. These events were accompanied by more significant improvement of RА course and increased functional abilities of joints. In patients from group III (absence of clinical effects), the level of antibodies to Infliximab before therapy was high, and it was increased by 22 week of treatment. It was shown that, in cases of initially high levels of endogenous anti-TNFα antibodies, clinical response to Infliximab therapy is likely to be reduced. Thus, it is possible to suggest that determination of initial TNFα and IL-10 levels, as well as starting levels of antibodies to Infliximab, and their changes in the course of therapy can be used as immunological parameters, thus allowing to predict the responses to Infliximab therapy. (Med. Immunol., 2008, vol. 10, N 2-3, pp 251-260).E. S. ZhugrovaV. I. MazurovA. M. LilaK. A. SyssoevS. V. LapinAreg A. TotolianSPb RAACIarticlerheumatoid arthritismethotrexatetnfαcytokinesinfliximabdas28haq functional indexImmunologic diseases. AllergyRC581-607RUMedicinskaâ Immunologiâ, Vol 10, Iss 2-3, Pp 251-260 (2014)
institution	DOAJ
collection	DOAJ
language	RU
topic	rheumatoid arthritis methotrexate tnfα cytokines infliximab das28 haq functional index Immunologic diseases. Allergy RC581-607
spellingShingle	rheumatoid arthritis methotrexate tnfα cytokines infliximab das28 haq functional index Immunologic diseases. Allergy RC581-607 E. S. Zhugrova V. I. Mazurov A. M. Lila K. A. Syssoev S. V. Lapin Areg A. Totolian DYNAMICS OF CYTOKINE PROFILE IN PATIENTS WITH RHEUMATOID ARTHRITIS AS INFLUENCED BY INFLIXIMAB (REMIKEID) ADMINISTRATION
description	Abstract. Rheumatoid arthritis (RA) is a chronic autoimmune systemic disease with predominantly destructive lesions of peripheral joints, with prevalence of 0.6 to 1.6% in general population. An important pathogenetic role in this disease is now attributed to imbalance between pro- and antiinflammatory cytokines. Clinical introduction of biological preparations, such as Infliximab (monoclonal antibodies to TNFα) within last years have changed therapeutic approach to treatment of rheumatic diseases. The aim of our research was to evaluate dynamics of pro- and antiinflammatory cytokine profile in the patients with rheumatoid arthritis (RА) during combined therapy with Infliximab and Methotrexate (MT). The study included 30 patients (27 females, 3 males, mean age of 52.5±2.0 years) who received combined therapy with МТ and Infliximab (Inx). Inx was initially injected at a single dose of 3 mg/kg intravenously, followed by administration 2 and 6 weeks later, and then repeated every 8 weeks. Regular examination of the patients included clinical and laboratory studies (ESR, levels of IL-6, IL-8, TNFα, IL-4, IL-10, GSM-CSF, IFNγ). Levels of antibodies against Infliximab in the groups of RА patients were determined before treatment and 22 weeks later. Efficiency of the therapy was estimated according to DAS28 3V Index and to HAQ Questionnaire.Upon decreased activity of disease, as assessed by DAS28, and improvement of HAQ parameters, a marked decrease in proinflammatory cytokine levels (IL-6, IL-8, TNFα) was detected, that confirming a pathogenetic significance of cytokine in RА patients. In patients with marked clinical effect (group I), an initially normal contents of TNFα was found in blood serum, and this group showed better response to Infliximab therapy, than groups II and III (resp., moderate and absent response) with initially high contents of TNFα and other cytokines, that was proven by correlations with ACR criteria and HAQ functional index. These events were accompanied by more significant improvement of RА course and increased functional abilities of joints. In patients from group III (absence of clinical effects), the level of antibodies to Infliximab before therapy was high, and it was increased by 22 week of treatment. It was shown that, in cases of initially high levels of endogenous anti-TNFα antibodies, clinical response to Infliximab therapy is likely to be reduced. Thus, it is possible to suggest that determination of initial TNFα and IL-10 levels, as well as starting levels of antibodies to Infliximab, and their changes in the course of therapy can be used as immunological parameters, thus allowing to predict the responses to Infliximab therapy. (Med. Immunol., 2008, vol. 10, N 2-3, pp 251-260).
format	article
author	E. S. Zhugrova V. I. Mazurov A. M. Lila K. A. Syssoev S. V. Lapin Areg A. Totolian
author_facet	E. S. Zhugrova V. I. Mazurov A. M. Lila K. A. Syssoev S. V. Lapin Areg A. Totolian
author_sort	E. S. Zhugrova
title	DYNAMICS OF CYTOKINE PROFILE IN PATIENTS WITH RHEUMATOID ARTHRITIS AS INFLUENCED BY INFLIXIMAB (REMIKEID) ADMINISTRATION
title_short	DYNAMICS OF CYTOKINE PROFILE IN PATIENTS WITH RHEUMATOID ARTHRITIS AS INFLUENCED BY INFLIXIMAB (REMIKEID) ADMINISTRATION
title_full	DYNAMICS OF CYTOKINE PROFILE IN PATIENTS WITH RHEUMATOID ARTHRITIS AS INFLUENCED BY INFLIXIMAB (REMIKEID) ADMINISTRATION
title_fullStr	DYNAMICS OF CYTOKINE PROFILE IN PATIENTS WITH RHEUMATOID ARTHRITIS AS INFLUENCED BY INFLIXIMAB (REMIKEID) ADMINISTRATION
title_full_unstemmed	DYNAMICS OF CYTOKINE PROFILE IN PATIENTS WITH RHEUMATOID ARTHRITIS AS INFLUENCED BY INFLIXIMAB (REMIKEID) ADMINISTRATION
title_sort	dynamics of cytokine profile in patients with rheumatoid arthritis as influenced by infliximab (remikeid) administration
publisher	SPb RAACI
publishDate	2014
url	https://doaj.org/article/21aea2d3e17f4045b69016b1763508be
work_keys_str_mv	AT eszhugrova dynamicsofcytokineprofileinpatientswithrheumatoidarthritisasinfluencedbyinfliximabremikeidadministration AT vimazurov dynamicsofcytokineprofileinpatientswithrheumatoidarthritisasinfluencedbyinfliximabremikeidadministration AT amlila dynamicsofcytokineprofileinpatientswithrheumatoidarthritisasinfluencedbyinfliximabremikeidadministration AT kasyssoev dynamicsofcytokineprofileinpatientswithrheumatoidarthritisasinfluencedbyinfliximabremikeidadministration AT svlapin dynamicsofcytokineprofileinpatientswithrheumatoidarthritisasinfluencedbyinfliximabremikeidadministration AT aregatotolian dynamicsofcytokineprofileinpatientswithrheumatoidarthritisasinfluencedbyinfliximabremikeidadministration
_version_	1718422529857552384

DYNAMICS OF CYTOKINE PROFILE IN PATIENTS WITH RHEUMATOID ARTHRITIS AS INFLUENCED BY INFLIXIMAB (REMIKEID) ADMINISTRATION

Ejemplares similares